To date, the diagnosis confirmation of ATRT requires both recognition of alterations in SMARCB1/SMARCA4 genes and specific immunohistochemical markers recognition expressed by rhabdoid cells such as epithelial membrane antigen (EMA), vimentin, smooth-muscle actin (SMA), and loss of nuclear expression of INI-1 protein [69]. The gene discussed is MUC1; the disease is atypical teratoid rhabdoid tumor.